Skip to main content
The Fiscal Times
Health Care
  • Free Newsletter
  • Featured
  • Budget
  • Taxes
  • Health Care
  • Social Security
  • The Debt
  • Search
The Fiscal Times

Search form

    • Free Newsletter
    • Featured
    • Budget
    • Taxes
    • Health Care
    • Social Security
    • The Debt
    • Search
  • Free Newsletter
  • Featured
  • Budget
  • Taxes
  • Health Care
  • Social Security
  • The Debt
  • Search
  • Business + Economy >>
  • Sectors + Companies >>
  • Health Care

Budget Battles

  • Republicans Want Strings Attached to California Disaster Aid
  • Biden Goes Out With a Bang in the Jobs Market
  • Trump Privately Pushes Senators for ‘One Big, Beautiful Bill’
  • Trump Considers Declaring National Emergency for Tariff Rollout
  • Trump Unloads: Grievances, Greenland and the Gulf of Mexico
  • Republicans Divided Over How to Pass Trump’s Agenda
  • Trump Pushes Johnson to Victory as Speaker

Newsletter

The Fiscal Times

Get the latest on Washington's budget battles and more with The Fiscal Times email newsletter every weekday. Sign up today.

Subscribe for FREE!

  • Patient at hospital

    It May Sound Awful, but We Really Do Need to Pay for Human Organs

    By Marc Joffe

    With dialysis being so expensive, onerous and ultimately fatal, kidney patients and taxpayers would be better off with more donations.

  • Feds' Big Bust: $1.3 Billion Health Insurance Fraud Takedown

    By Rob Garver

    On the same day that Republican members of the Senate released a pair of bills aimed at repealing and replacing the Affordable Care Act, the Department of Justice highlighted a problem with the...

  • FILE PHOTO: An attendee uses a new iPhone X during a presentation for the media in Beijing, China October 31, 2017. REUTERS/Thomas Peter/File Photo

    Where Do You Store Your Medical Info? Apple Wants It to Be Your iPhone

    By Christina Farr, CNBC

    Imagine turning to your iPhone for all your health and medical information — every doctor's visit, lab test result, prescription and other health information, all available in a snapshot on your...

  • CEO and vice president hospital affairs

    How American Health Care Became a Big, Broken Business

    By Yuval Rosenberg

    Who’s to blame for the sad state of the American health care system in 2017? The short answer, as Dr. Elisabeth Rosenthal details in her new book “An American Sickness: How Healthcare Became Big...

  • Soda Pop

    Why You Should Think Twice Before Drinking That Can of Soda

    By Barbara Moran

    New research suggests that excess sugar—especially the fructose in sugary drinks—might damage your brain.

  • 9) BCBS of Florida

    One Major Obamacare Insurance Company Is Close to Break Even This Year

    By Eric Pianin

    Despite high premiums and diminished consumer choices that might deter consumers from enrolling in Obamacare, a new financial analysis concludes that the individual health insurance market has shaken...

  • USA-HEALTHCARE-CANCER-COSTS

    New Cancer Drugs Show Promise – and Sky-High Prices

    By DEENA BEASLEY, Reuters

    Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year. The drugs' success...

  • A growing number of patients are being denied access to newer oral chemotherapy drugs for cancer pills with annual price tags of more than $75,000.

    The Billion Dollar Drug for Opioid Victims Has a Problem: It’s Addictive

    By Andrew L Yarrow

    Maryland Gov. Larry Hogan’s executive order earlier this month, declaring the state’s opioid addiction crisis a state of emergency, is yet another example of the state’s leadership in addressing a...

  • FILE PHOTO OF PILLS OF ALL KINDS.

    Pfizer Chief Says Government Efforts to Contain Drug Prices Will Backfire

    By Eric Pianin

    Ian C. Read, Pfizer’s hard-edged, Scottish-born CEO and chairman, has been unapologetic about his company’s dubious pricing practices. Last week, he gave no ground on the larger question about...

  • Research Scientist

    Trump’s Big Cuts to Medical Research May Not Get Past Congress

    By Eric Pianin

    NIH, Donald Trump, Paul Ryan, Joe Biden, cancer research, National Institutes of Health

  • EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company are seen in Washington

    Will Mylan’s $300 Generic EpiPen Packs Quell Pricing Firestorm?

    By Eric Pianin

    Drugmaker Mylan, the maker of the EpiPen auto-injection device vital in saving the lives of victims of extreme allergic reactions, caved under enormous political pressure on Monday and announced it...

  • EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016.  REUTERS/Jim Bourg

    Did Mylan Just Cut the Price of the EpiPen? Not Really

    By Eric Pianin

    Mylan pharmaceutical company is engaged in deep damage control in response to complaints by Democratic presidential nominee Hillary Clinton, senior U.S. senators and tens of thousands of irate...

  • Two Big Reasons Prescription Drug Prices Are So Much Higher in the US

    By Eric Pianin

    It’s no secret that Americans have long spent far more on prescription drugs, on average, than consumers in most other industrialized countries. Per capita prescription drug spending in the United...

  • The Latest Sign That the Obamacare Exchanges Aren’t Working in Many Markets

    By Eric Pianin

    In the wake of Aetna’s recent announcement that it was pulling up stakes in 11 of 15 states where it had been selling insurance on Obamacare exchanges, there are more alarming signs that other major...

  • Epi-Pen Maker Enters the Pharmaceutical Industry’s Hall of Shame

    By Eric Pianin

    One of a parent’s worst nightmares is seeing a young child gasping for breath as a result of an allergic attack and being powerless to do anything about it. Sen. Amy Klobuchar (D-MN) still recalls...

  • Load More Stories
Quantcast
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms of Use
Follow Your Money
© 2009-2025 The Fiscal Times. All rights reserved.

We use cookies on this site to enhance your user experience

By clicking the accept link, you agree to us doing so.